Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 -- Zai Lab Limited today announced that the Center for Drug Evaluation of the National Medical Products Administration granted Breakthrough...

Related Keywords

China ,Shanghai ,Taiwan ,United States ,Hong Kong ,Cambridge ,Cambridgeshire ,United Kingdom ,Macau ,Chinese ,Christine Chiou Lina Zhang ,Jennifer Chang Xiaoyu Chen ,Harald Reinhart ,Zai Lab ,Exchange Commission ,Head Of Global Development ,National Medical Products Administration ,Zai Lab Forward ,Zai Lab Limited ,China International Nonproprietary Name ,Lab Limited ,Drug Evaluation ,Breakthrough Therapy Designation ,Global Development ,Infectious Diseases ,Greater China ,Private Securities Litigation Reform Act ,Markets ,